NCT03510767View on ClinicalTrials.gov

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

August 15, 2022

Study Completion Date

August 31, 2024

Conditions
Relapsed or Refractory Lymphoma or Advanced Cancer
Interventions
DRUG

TQ-B3525

TQ-B3525 p.o. qd

Trial Locations (1)

300121

RECRUITING

People's Hospital of Tianjin, Tianjin

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY